Evidence map›Paper›PMID 26889818›Full record

ReviewHuman vaccines & immunotherapeutics2016

Ipilimumab (Anti-Ctla-4 Mab) in the treatment of metastatic melanoma: Effectiveness and toxicity management.

Paola Savoia, Chiara Astrua, Paolo Fava

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Human vaccines & immunotherapeutics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed.

  1. A multidomain peptide hydrogel-liposome composite for controlled release of a cyclic dinucleotide in oral cancer.Journal of controlled release : official journal of the Controlled Release Society · 2026
    Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Paola Savoiaa Department of Medical Sciences , University of Turin , Turin , Italy.
Chiara Astruaa Department of Medical Sciences , University of Turin , Turin , Italy.
Paolo Favaa Department of Medical Sciences , University of Turin , Turin , Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the last years the onset of new therapies changed the management of malignant melanoma. Anti CTLA-4 antibody ipilimumab was the first drug to achieve a significant improvement in survival of advanced stage melanoma. This new therapeutic agent is characterized by a number of side effects that are totally different from those of traditional chemotherapy, mainly caused by the immune system activation. The purpose of this paper is to underline the central role of ipilimumab in the treatment of metastatic melanoma and to characterize related adverse events in terms of incidence, duration and severity of presentation. The early recognition of these side effects is crucial in order to ensure an appropriate management of the toxicities, thus reducing the long term clinical sequelae and the inappropriate treatment discontinuation.

Indexed as

Antibodies, MonoclonalClinical Trials as TopicCTLA-4 AntigenCutaneous Malignant MelanomaHumansImmunotherapyIpilimumabMelanomaSkin NeoplasmsAntibodies, MonoclonalCTLA-4 AntigenCTLA4 protein, humanIpilimumabanti-CTL-A4immunotherapyipilimumabmelanoma treatmenttoxicity

Identifiers

PMID26889818
PMCPMC4963052

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.